Phase II study of low dose decitabine (5-aza-deoxycytidine) with interferon alfa-2b in advanced renal cell carcinoma.
Phase of Trial: Phase II
Latest Information Update: 23 Dec 2011
At a glance
- Drugs Decitabine; Interferon alpha-2b
- Indications Renal cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 20 Jan 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 20 Jan 2010 Planned end date changed from 1 Oct 2009 to 1 Nov 2009 as reported by ClinicalTrials.gov.